1-8 of 8
Yan Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma

Bin Shen, Jue-Ping Shi, Zhi-Xuan Zhu, Zhi-Dong He, Shen-Yan Liu, Wan Shi, Yong-Xian Zhang, Hai-Yan Ying, Jie Wang, Rui-Feng Xu, Fei Fang, Harrison Xuesong Chang, Zhui Chen, Nan-Nan Zhang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1479–1492.
https://doi.org/10.1158/1535-7163.MCT-23-0096
Published: 01 December 2023
View article titled, EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma
Open the PDF for EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract B068: The establishment of a large tumor organoid biobank using a well characterized/annotated patient-derived xenograft (PDX) library to enable drug discovery and translational research

Xiaoxi Xu, Limei Shang, Lili Wang, Chunmei Li, Yan Liu, Peng Han, Zhongman Sun, Yaping Qu, Likun Zhang, Bonnie Xiaobo Chen, Davy Xuesong Ouyang, Yujun Huang, Henry Qixiang Li
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B068.
https://doi.org/10.1158/1535-7163.TARG-19-B068
Published: 01 December 2019
View article titled, Abstract B068: The establishment of a large tumor organoid biobank using a well characterized/annotated patient-derived xenograft (PDX) library to enable drug discovery and translational research
Journal Articles

Abstract A212: Preclinical efficacy of MEK inhibition in a K-Ras driven cholangiocarcinoma preclinical model

Mingjie Dong, Xianqiong Liu, Katja Evert, Kirsten Utpatel, Shanshan Zhang, Li Che, John Gordan, Diego Calvisi, Matthias evert, Yan Liu, Xin Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A212.
https://doi.org/10.1158/1535-7163.TARG-17-A212
Published: 01 January 2018
View article titled, Abstract A212: Preclinical efficacy of MEK inhibition in a K-Ras driven cholangiocarcinoma preclinical model
Journal Articles

Abstract A39: Quantitative FRET technology for SUMOylation cascade and high-throughput screening assay for SUMOylation inhibitor in cancer drug discovery

Jiayu Liao, Hilda Wiryawan, Yang Song, Yan Liu, Ling Jiang, Harbani Kaur Malik, Amanda N. Saaredra
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): A39.
https://doi.org/10.1158/1535-7163.PMS-A39
Published: 01 May 2014
View article titled, Abstract A39: Quantitative FRET technology for SUMOylation cascade and high-throughput screening assay for SUMOylation inhibitor in cancer drug discovery
Journal Articles

Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells

Yan Liu, Shi-Yong Sun, Taofeek K. Owonikoko, Gabriel L. Sica, Walter J. Curran, Fadlo R. Khuri, Xingming Deng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (1): 45–56.
https://doi.org/10.1158/1535-7163.MCT-11-0578
Published: 09 January 2012
View article titled, Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells
Open the PDF for Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Abstract A130: Fragment-based discovery and optimization of Rho kinase inhibitors.

Yan Liu, Binglin Wang, Ronil A. Patel, Nan Sun, Shen-Shu Sung, Roberta Pireddu, Nicholas J. Lawrence, Said M. Sebti, Rongshi Li
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A130.
https://doi.org/10.1158/1535-7163.TARG-11-A130
Published: 12 November 2011
View article titled, Abstract A130: Fragment-based discovery and optimization of Rho kinase inhibitors.
Journal Articles

Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab

Zhaofei Liu, Yan Liu, Bing Jia, Huiyun Zhao, Xiaona Jin, Fang Li, Xiaoyuan Chen, Fan Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (8): 2297–2308.
https://doi.org/10.1158/1535-7163.MCT-10-0444
Published: 09 August 2010
View article titled, Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using <sup>90</sup>Y-Labeled Fully Human Antibody Panitumumab
Open the PDF for Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using <sup>90</sup>Y-Labeled Fully Human Antibody Panitumumab in another window
Includes: Supplementary data
Journal Articles

Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo

Jun-Yan Liu, See-Hyoung Park, Christophe Morisseau, Sung Hee Hwang, Bruce D. Hammock, Robert H. Weiss
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (8): 2193–2203.
https://doi.org/10.1158/1535-7163.MCT-09-0119
Published: 14 August 2009
View article titled, Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile <em>in vivo</em>
Open the PDF for Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile <em>in vivo</em> in another window
Includes: Supplementary data